1. Home
  2. SRPT vs FTAIN Comparison

SRPT vs FTAIN Comparison

Compare SRPT & FTAIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SRPT
  • FTAIN
  • Stock Information
  • Founded
  • SRPT 1980
  • FTAIN N/A
  • Country
  • SRPT United States
  • FTAIN United States
  • Employees
  • SRPT N/A
  • FTAIN 580
  • Industry
  • SRPT Biotechnology: Pharmaceutical Preparations
  • FTAIN Misc Corporate Leasing Services
  • Sector
  • SRPT Health Care
  • FTAIN Industrials
  • Exchange
  • SRPT Nasdaq
  • FTAIN Nasdaq
  • Market Cap
  • SRPT 1.7B
  • FTAIN N/A
  • IPO Year
  • SRPT 1997
  • FTAIN N/A
  • Fundamental
  • Price
  • SRPT $17.97
  • FTAIN $25.49
  • Analyst Decision
  • SRPT Buy
  • FTAIN
  • Analyst Count
  • SRPT 25
  • FTAIN 0
  • Target Price
  • SRPT $61.57
  • FTAIN N/A
  • AVG Volume (30 Days)
  • SRPT 8.0M
  • FTAIN N/A
  • Earning Date
  • SRPT 08-06-2025
  • FTAIN N/A
  • Dividend Yield
  • SRPT N/A
  • FTAIN N/A
  • EPS Growth
  • SRPT N/A
  • FTAIN N/A
  • EPS
  • SRPT N/A
  • FTAIN N/A
  • Revenue
  • SRPT $2,233,371,000.00
  • FTAIN N/A
  • Revenue This Year
  • SRPT $26.87
  • FTAIN N/A
  • Revenue Next Year
  • SRPT $3.15
  • FTAIN N/A
  • P/E Ratio
  • SRPT N/A
  • FTAIN N/A
  • Revenue Growth
  • SRPT 59.15
  • FTAIN N/A
  • 52 Week Low
  • SRPT $16.88
  • FTAIN N/A
  • 52 Week High
  • SRPT $154.13
  • FTAIN N/A
  • Technical
  • Relative Strength Index (RSI)
  • SRPT 28.43
  • FTAIN 63.85
  • Support Level
  • SRPT $17.31
  • FTAIN $25.21
  • Resistance Level
  • SRPT $19.74
  • FTAIN $25.48
  • Average True Range (ATR)
  • SRPT 1.04
  • FTAIN 0.14
  • MACD
  • SRPT 0.87
  • FTAIN 0.04
  • Stochastic Oscillator
  • SRPT 45.83
  • FTAIN 100.00

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

About FTAIN FTAI Aviation Ltd. 8.25% Fixed - Rate Reset Series C Cumulative Perpetual Redeemable Preferred Shares

FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.

Share on Social Networks: